Literature DB >> 22275923

The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia.

A I Carkanat1, A Abdurrahman, O Abakay, S Cengizhan, S H Selimoglu, A Senyigit.   

Abstract

BACKGROUND: Malignant pleural Mesothelioma (MPM) is a very rarely encountered tumor in the normal population.
OBJECTIVES: To investigate the variations in incidence of MPM in Southeast region of Turkey.
METHODS: We retrospectively investigated the data of 161 MPM patients who were diagnosed from January 2000 to December 2009. The residential areas were determined according to asbestos exposure which plays a role in MPM etiology; previously reported as having asbestos (Region 1) and asbestos has not been determined previously (Region 2).
RESULTS: One hundred nine (109) of the patients (67.7%) included from the Region 1 and 52 of them (32.3%) included from the Region 2. MPM incidence of the last decade was 3.9/100,000 person/year for the whole region. In Region 1, 2000-2004 incidences was 12.6/100,000 person/year and 2005-2009 incidences was 14.9/100,000 person/year. In Region 2, 2000-2004 incidences was 0.4/100,000 person/year and 2005-2009 incidences was 1.0/100,000 person/year. According to the recently conducted incidence studies in our region, MPM incidence increased in region 1 and decreased in region 2. The number of patients applying to our hospital has increased in the last three years.
CONCLUSION: This increase, in Region 1 may be associated with continuous use of asbestos.

Entities:  

Keywords:  Southeast Turkey; asbestosis; incidence; mesothelioma

Mesh:

Substances:

Year:  2011        PMID: 22275923      PMCID: PMC3260992     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  21 in total

1.  Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey.

Authors:  A Senyiğit; C Babayiğit; M Gökirmak; F Topçu; E Asan; M Coşkunsel; R Işik; M Ertem
Journal:  Respiration       Date:  2000       Impact factor: 3.580

2.  Mortality in miners and millers of crocidolite in Western Australia.

Authors:  B K Armstrong; N H de Klerk; A W Musk; M S Hobbs
Journal:  Br J Ind Med       Date:  1988-01

3.  Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.

Authors:  Selma Metintas; Muzaffer Metintas; Irfan Ucgun; Ulku Oner
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

4.  Cancer statistics, 1993.

Authors:  C C Boring; T S Squires; T Tong
Journal:  CA Cancer J Clin       Date:  1993 Jan-Feb       Impact factor: 508.702

5.  Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust.

Authors:  S Yazicioglu; R Ilçayto; K Balci; B S Sayli; B Yorulmaz
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

6.  Demographic patterns for mesothelioma in the United States.

Authors:  R R Connelly; R Spirtas; M H Myers; C L Percy; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1987-06       Impact factor: 13.506

7.  Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.

Authors:  Z T Selçuk; L Cöplü; S Emri; A F Kalyoncu; A A Sahin; Y I Bariş
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

8.  Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.

Authors:  L Tammilehto; P Maasilta; S Kostiainen; P Appelqvist; L R Holsti; K Mattson
Journal:  Respiration       Date:  1992       Impact factor: 3.580

9.  Malignant pleural mesothelioma: a clinicopathological study.

Authors:  J C Qua; U N Rao; H Takita
Journal:  J Surg Oncol       Date:  1993-09       Impact factor: 3.454

10.  Recent trends in mesothelioma incidence in the United States.

Authors:  R Spirtas; G W Beebe; R R Connelly; W E Wright; J M Peters; R P Sherwin; B E Henderson; A Stark; B M Kovasznay; J N Davies
Journal:  Am J Ind Med       Date:  1986       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.